The Trouble With Ozempic
Weight-loss drugs show great promise—but they also pose challenges that pharmaceutical innovation alone can’t overcome.
This is an edition of The Atlantic Daily, a newsletter that guides you through the biggest stories of the day, helps you discover new ideas, and recommends the best in culture. Sign up for it here.
Thanks to extraordinary demand for the drugs Ozempic and Wegovy, which cause weight loss, pharmaceutical companies are racing to bring even more potent anti-obesity treatments to market. But, as my colleague Yasmin Tayag wrote this week in The Atlantic, current challenges around these drugs’ potential for misuse, and barriers to safe access, aren’t likely to subside. I chatted with Yasmin about what might happen next.
But first,.
